阅读说明：本技术 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品 (Combination of regorafenib and a PD-1/PD-L1(2) inhibitor for the treatment of cancer ) 是由 S.霍夫 L.勒泽 D.佐普夫 F.基斯林 W.莱德勒 D.多莱舍尔 于 2018-05-25 设计创作，主要内容包括：本发明涉及用于治疗、预防或管理人类和其它哺乳动物的疾病和病况,包括过度增殖障碍如癌症的包含瑞格菲尼或其水合物、溶剂化物、代谢物或可药用盐或其多晶型物和PD-1/PD-L1(2)抑制剂的药物组合物和组合产品。(The present invention relates to pharmaceutical compositions and combinations comprising regorafenib, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof, or polymorph thereof, and a PD-1/PD-L1(2) inhibitor for the treatment, prevention or management of diseases and conditions, including hyperproliferative disorders such as cancer, in humans and other mammals.)